Monarch
Medical Technologies, the leader in precision insulin dosing
technology for optimized glycemic management, presented two posters at
the American Association of Clinical Endocrinologists (AACE) Annual
Meeting. The two retrospective studies analyze a database of nearly one
million blood glucose readings from approximately 45,000 patients who
were prescribed intravenous (IV) insulin dose recommendations using the EndoTool®
Glucose Management System.
The first poster, “Measure
of Safety for Q2Hour vs. Q1Hour Glucose Checks for Intravenous Insulin
Dosing,” aimed to determine the safety and efficacy of two-hour
blood glucose checks when using the electronic glucose management system
(eGMS), EndoTool.
Many paper protocols and eGMS dosing algorithms for IV insulin make
recommendations to change from hourly (q1hour) blood glucose checks to
every two-hour (q2hour) checks based on various measures of the
subject’s blood glucose stability. However, it is suggested that the
algorithms should be evaluated based on the incidence of hypoglycemia
and variability. This analysis found that measures of hypoglycemia and
control were superior for q2hour checks compared to q1hour checks,
confirming that the EndoTool algorithm for recommendation of q2hour
checks is appropriate.
“The ability to move to q2hour blood glucose checks benefits the patient
and significantly improves nursing workflow and the cost of care,” said
Laurel Fuqua, Executive VP & Chief Clinical Officer of Monarch Medical
Technologies. “However, this transition must be made at the appropriate
time to ensure patient safety. This study confirms that the EndoTool
algorithm is appropriate and safe in its recommendation.”
The second poster, “Goal
Range Effect on Hypoglycemia Incidence for Intravenous Insulin Dosing”
examined the effect of goal range on the incidence of hypoglycemia in
patients receiving intravenous insulin therapy.
Most eGMS and paper protocols require users to set an upper goal and
lower goal, referred to as the goal range. Target blood glucose values
for the glucose range vary, and limited research exists to study the
effect of goal range on hypoglycemia. This retrospective analysis
stratified two goal ranges, 100 to 140 mg/dL and 160 to 200 mg/dL, and
analyzed the incidence of hypoglycemia in sub-ranges of 10 mg/dL. The
analysis concluded that as the upper goal is lowered, reducing the
spread of the goal range has the potential to reduce hypoglycemia.
“While the EndoTool algorithm has statistically eliminated hypoglycemia,
we continue to look for enhancements to completely eliminate the risk of
hypoglycemia,” said W. Patrick Burgess, Founder & Inventor of EndoTool.
“Further research is required; however, our analysis supported the
hypothesis that reducing the goal range spread as the upper goal is
lowered could make a significant difference in reducing hypoglycemia.”
To download the two posters and learn more about Monarch Medical
Technologies, please visit monarchmedtech.com.
About Monarch Medical Technologies
Monarch Medical Technologies is the leading provider of electronic
systems for inpatient glycemic management. Monarch’s EndoTool® Glucose
Management System offers personalized dosing recommendations for
intravenous and subcutaneous insulin therapy. As a Class II FDA-cleared,
patented software suite, EndoTool has been chosen by more than 300
hospitals to provide unsurpassed patient-specific glycemic control
across a broad population of patients, and ultimately deliver better,
safer care. For more information, please visit monarchmedtech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190429005531/en/